Condition: Lung Cancer (Diagnosis) · Sponsor: Vejle Hospital
The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease). Patients with COPD will be recruited in general practice, where they will have a blood sample drawn. All data will be analyzed by the machine learning model, and patients with increased risk of lung cancer will be referred for a low-dose CT scan of the chest. The primary objective of the study is to evaluate the feasibility of AI and DNA methylation-based risk stratification for lung cancer in patients with COPD in a primary care setting. The secondary objectives are to evaluate the safety of the risk stratification approach, the potential effects on quality of life and wellbeing, to gain insight into the patient and physician perspectives, and to estimate the health economic consequences.
This description comes directly from the study's public registry record.
Sara Witting Christensen WC Wen, MD, PhD · +45 79406511 · sara.witting.christensen.wen@rsyd.dk
Lene Horsted, Study nurse · +45 79409946 · breathe@rsyd.dk
Always discuss trial participation with your own doctor first.
| Lillebaelt Hospital Vejle, University Hospital of Southern Denmark | Vejle, Denmark | Recruiting |
| General practices, Vejle area | Vejle, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07552584